AI assistant
Wave Life Sciences Ltd. — Director's Dealing 2020
Feb 21, 2020
31900_dirs_2020-02-20_192dee7b-202e-458d-8a52-8e3a49ed8503.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2020-02-18
Reporting Person: BOLNO PAUL (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-18 | Ordinary Shares | S | 11451 | $7.85 | Disposed | 319758 | Direct |
Footnotes
F1: On February 18, 2020, the reporting person sold 11,451 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan.
F2: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.148 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.